Related Experiment Video
Updated: Aug 9, 2025
Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
Published on: August 20, 2007
Clinical adoptive regulatory T Cell therapy: State of the art, challenges, and prospective
Leila Amini1,2, Jaspal Kaeda1, Enrico Fritsche1
1Berlin Center for Advanced Therapies, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Abstract:
Rejection of solid organ transplant and graft versus host disease (GvHD) continue to be challenging in post transplantation management. The introduction of calcineurin inhibitors dramatically improved recipients' short-term prognosis. However, long-term clinical outlook remains poor, moreover, the lifelong dependency on these toxic drugs leads to chronic deterioration of graft function, in particular the renal function, infections and de-novo malignancies. These observations led investigators to identify alternative therapeutic options to promote long-term graft survival, which could be used concomitantly, but preferably, replace pharmacologic immunosuppression as standard of care. Adoptive T cell (ATC) therapy has evolved as one of the most promising approaches in regenerative medicine in the recent years. A range of cell types with disparate immunoregulatory and regenerative properties are actively being investigated as potential therapeutic agents for specific transplant rejection, autoimmunity or injury-related indications. A significant body of data from preclinical models pointed to efficacy of cellular therapies. Significantly, early clinical trial observations have confirmed safety and tolerability, and yielded promising data in support of efficacy of the cellular therapeutics. The first class of these therapeutic agents commonly referred to as advanced therapy medicinal products have been approved and are now available for clinical use. Specifically, clinical trials have supported the utility of CD4+CD25+FOXP3+ regulatory T cells (Tregs) to minimize unwanted or overshooting immune responses and reduce the level of pharmacological immunosuppression in transplant recipients. Tregs are recognized as the principal orchestrators of maintaining peripheral tolerance, thereby blocking excessive immune responses and prevent autoimmunity. Here, we summarize rationale for the adoptive Treg therapy, challenges in manufacturing and clinical experiences with this novel living drug and outline future perspectives of its use in transplantation.
Insights
Adoptive regulatory T cell (Treg) therapy shows promise for improving long-term transplant survival by reducing reliance on toxic immunosuppressants. This regenerative medicine approach offers a potential alternative to current treatments for graft rejection and GvHD.
Area of Science:
- Immunology
- Regenerative Medicine
- Transplantation Science
Background:
- Solid organ transplant rejection and graft-versus-host disease (GvHD) remain significant challenges in post-transplant care.
- Current calcineurin inhibitor-based immunosuppression improves short-term outcomes but leads to long-term graft dysfunction, infections, and malignancies.
- There is a critical need for alternative therapies to enhance long-term graft survival and reduce the toxicity of current immunosuppressive regimens.
Purpose of the Study:
- To explore adoptive T cell (ATC) therapy, specifically regulatory T cells (Tregs), as a promising alternative for managing transplant rejection and GvHD.
- To review the rationale, manufacturing challenges, and clinical experiences with adoptive Treg therapy in transplantation.
- To outline future perspectives for Treg therapy in improving long-term transplant outcomes.
Main Methods:
- Review of preclinical data and early clinical trial observations on the efficacy and safety of cellular therapies in transplantation.
- Focus on CD4+CD25+FOXP3+ regulatory T cells (Tregs) for their role in maintaining peripheral tolerance and modulating immune responses.
- Analysis of the potential of Tregs to minimize immune responses and reduce pharmacological immunosuppression.
Main Results:
- Preclinical models demonstrate the efficacy of cellular therapies.
- Early clinical trials indicate that adoptive Treg therapy is safe and well-tolerated.
- Tregs are identified as key regulators of peripheral tolerance, capable of preventing excessive immune responses.
Conclusions:
- Adoptive Treg therapy represents a novel and promising approach in regenerative medicine for transplantation.
- Tregs offer a potential strategy to reduce reliance on conventional immunosuppressants, thereby mitigating long-term toxicity and improving graft function.
- Further clinical investigation and manufacturing optimization are crucial for the widespread adoption of Treg therapy in clinical practice.
